Kamada (KMDA) Income from Non-Controlling Interests (2019 - 2022)
Kamada (KMDA) posted quarterly Income from Non-Controlling Interests of -$108000.0 for Q1 2022, down 47.95% year-on-year from -$207473.7 in Q1 2021, and down 47.95% on a QoQ basis from -$73000.0 in Q1 2021.
Kamada (KMDA) Income from Non-Controlling Interests (2019 - 2022) Analysis & Trends
Kamada (KMDA) has reported Income from Non-Controlling Interests for 4 consecutive years, with -$108000.0 the latest figure, recorded in Q1 2022.
- Quarterly Income from Non-Controlling Interests fell 47.95% year-over-year to -$108000.0 in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $134000.0 (changed N/A YoY) and the FY2021 annual result came in at $185000.0, down 78.88% from the prior year.
- Income from Non-Controlling Interests retreated to -$108000.0 in Q1 2022 per KMDA's latest filing, from -$73000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for KMDA reached as high as $241000.0 in Q1 2020 and fell as low as -$108000.0 in Q1 2022.
- A 4-year average of $33500.0 and a median of $500.0 in 2019 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2020 — Income from Non-Controlling Interests jumped 225.68% — and 2021, when it plunged 130.29%.
- Year by year, Income from Non-Controlling Interests stood at $74000.0 in 2019, then soared by 225.68% to $241000.0 in 2020, then tumbled by 130.29% to -$73000.0 in 2021, then sank by 47.95% to -$108000.0 in 2022.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$108000.0, -$73000.0, and $241000.0 for Q1 2022, Q1 2021, and Q1 2020 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.85 Bn | 32.11 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.48 Bn | 30.54 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.33 Bn | 18.53 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.43 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | - |
| 10 | Kamada | 402.37 Mn | 329.22 Mn | 19.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -108,000.00 |
| Mar 31, 2021 | -73,000.00 |
| Mar 31, 2020 | 241,000.00 |
| Mar 31, 2019 | 74,000.00 |